(1).jpg)
KAJIAN PUSTAKA: BIOMARKER DIAGNOSIS DAN THARGETED THERAPHY PSORIATIC ARTHRITIS
Abstract
Abstrak: Kajian Pustaka: Biomarker Diagnosis Dan Thargeted Theraphy Psoriatic Arthritis. Psoriatic arthritis (PsA) adalah radang sendi kronis yang berhubungan dengan psoriasis (PsO) dan ditemukan pada sekitar 20% pasien dengan PsO. Diperkirakan prevalensi PsA 0,05% sampai 0,25% pada populasi umum dan sekitar 6% sampai 41% pada pasien psoriasis. Dalam penegakan diagnosis PsA dapat menggunakan berbagai kriteria diagnosis. Kuesioner yang berisi pertanyaan penting tentang gejala sendi, kekakuan di pagi hari, dan fungsi dapat membantu diagnosis PsA. Terdapat tiga kuesioner yang sering digunakan untuk skrining pasien dengan psoriasis dan artritis. Biomarker adalah penanda yang objektif dan berguna untuk diagnosis dan evaluasi perubahan status fisiologis pasien dengan PsA. Sampai saat ini, tidak ada biomarker khusus penyakit yang telah diidentifikasi untuk PsA. Akibat kemajuan dalam patogenesis PsA kini telah diidentifikasi beberapa jalur inflamasi yang didorong oleh sitokin dan telah berhasil menargetkan beberapa inhibitor spesifik. Pengobatan PsA didasarkan pada terapi non farmakologis dan farmakologis. IL-17 atau IL-23 adalah kunci dalam perkembangan penyakit PsA. Penggunaan molekul yang memblokir sitokin ini menunjukkan manfaat dalam mengendalikan aktivitas penyakit dan mencegah perkembangannya
Keywords
Full Text:
PDFReferences
Azuaga, A.B.; Frade-Sosa, B.; Laiz, A.; Estrada, P.; Prior-Español, A.; Horcada, L.; Polino, L.; Moreno, M.; Moragues, C.; Urruticoechea-Arana, A.; et al. Effectiveness of Ustekinumab in Patients with Psoriatic Arthritis in a Real-
World, Multicenter Study. Clin. Rheumatol. 2020, 39, 2963–2971
Azuaga, A.B.; Ramírez, J.; Cañete, J.D. Psoriatic Arthritis: Pathogenesis and Targeted Therapies. Int. J. Mol. Sci. 2023, 24, 4901
Burlando M., Cozzani E., Schiavetti I., Cicchelli S., Repetto M., Rossotto G.,
Scaparro E., Parodi A. The STRIPP Questionnaire (Screening Tool for Rheumatologic Investigation in Psoriatic Patients) as a New Tool for the
Diagnosis of Early Psoriatic Arthritis. G. Ital. Dermatol. Venereol. 2020;155:294–298
Caso F., Costa L., Chimenti M.S., Navarini L., Punzi L. Pathogenesis of Psoriatic Arthritis. Crit. Rev. Immunol. 2019;39:361–377
Coates L.C., Savage L., Waxman R., Moverley A.R., Worthington S., Helliwell P.S. Comparison of screening questionnaires to identify psoriatic arthritis in a primary-care population: A cross-sectional study. Br. J. Dermatol. 2016;175:542–548
Coates, L.C.; Soriano, E.R.; Corp, N.; Bertheussen, H.; Callis Duffin, K.; Campanholo, C.B.; Chau, J.; Eder, L.; Fernández-Ávila, D.G.; FitzGerald, O.; et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated Treatment Recommendations for Psoriatic Arthritis 2021.
Nat. Rev. Rheumatol. 2022, 18, 465–479
Colombel, J.F.; Sendid, B.; Jouault, T.; Poulain, D. Secukinumab Failure in Crohn’s Disease: The Yeast Connection? Gut 2013, 62, 800–80
Connolly M., Mullan R.H., McCormick J., Matthews C., Sullivan O., Kennedy A., FitzGerald O., Poole A.R., Bresnihan B., Veale D.J., et al. Acute-Phase Serum Amyloid a Regulates Tumor Necrosis Factor α and Matrix Turnover and Predicts Disease Progression in Patients with Inflammatory Arthritis Before and After Biologic Therapy. Arthritis Rheum. 2012;64:1035–1045
Ghasemi S., Sardari K., Mirshokraei P., Hassanpour H. In Vitro Study of Matrix Metalloproteinases 1, 2, 9, 13 and Serum Amyloid A mRNAs Expression in Equine Fibroblast-Like Synoviocytes Treated with Doxycycline. Can. J. Vet. Res. 2018;82:82–88
Gibson D.S., Rooney M.E., Finnegan S., Qiu J., Thompson D.C., Labaer J., Pennington S.R., Duncan M.W. Biomarkers in Rheumatology, Now and in the Future. Rheumatology. 2012;51:423–433
Gladman D.D., Schentag C.T., Tom B.D., Chandran V., Brockbank J., Rosen C., Farewell V.T. Development and Initial Validation of a Screening Questionnaire for Psoriatic Arthritis: The Toronto Psoriatic Arthritis Screen (ToPAS) Ann. Rheum. Dis. 2009;68:497–501
Gossec, L.; Baraliakos, X.; Kerschbaumer, A.; de Wit, M.; McInnes, I.; Dougados, M.; Primdahl, J.; McGonagle, D.G.; Aletaha, D.; Balanescu, A.; et al. EULAR Recommendations for the Management of Psoriatic Arthritis with Pharmacological Therapies: 2019 Update. Ann. Rheum. Dis. 2020, 79, S700–S712
Gupta S, Syrimi Z, Hughes DM, Zhao SS. Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int. 2021 Feb;41(2):275-284
Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: A literature review. Best Pract Res Clin Rheumatol. 2021 Jun;35(2):10169
Kristensen, L.E.; Keiserman, M.; Papp, K.; McCasland, L.; White, D.; Lu, W.; Wang, Z.; Soliman, A.M.; Eldred, A.; Barcomb, L.; et al. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Results from the Randomised, Double-Blind, Phase 3 KEEPsAKE 1 Trial. Ann. Rheum. Dis. 2022, 81, 225–231
Leone, G.M.; Mangano, K.; Petralia, M.C.; Nicoletti, F.; Fagone, P. Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy. J. Clin. Med. 2023, 12, 1630
Li, X.; Andersen, K.M.; Chang, H.Y.; Curtis, J.R.; Alexander, G.C. Comparative Risk of Serious Infections among Real-World Users of Biologics for Psoriasis or Psoriatic Arthritis. Ann. Rheum. Dis. 2020, 79, 285–291.
McArdle A., Pennington S., FitzGerald O. Clinical Features of Psoriatic Arthritis: A Comprehensive Review of Unmet Clinical Needs. Clin. Rev. Allergy Immunol. 2018;55:271–294
McInnes, I.B.; Asahina, A.; Coates, L.C.; Landewé, R.; Merola, J.F.; Ritchlin, C.T.; Tanaka, Y.; Gossec, L.; Gottlieb, A.B.; Warren, R.B.; et al. Bimekizumab in Patients with Psoriatic Arthritis, Naive to Biologic Treatment: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial (BE OPTIMAL). Lancet 2023, 401, 25–37
Mease P.J., Gladman D.D., Helliwell P., Khraishi M.M., Fuiman J., Bananis E., Alvarez D. Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. J. Am. Acad. Dermatol. 2014;71:649–655
Mease, P.J.; Helliwell, P.S.; Gladman, D.D.; Poddubnyy, D.; Baraliakos, X.; Chakravarty, S.D.; Kollmeier, A.P.; Hsia, E.C.; Xu, X.L.; Sheng, S.; et al. Efficacy of Guselkumab on Axial Involvement in Patients with Active Psoriatic
Arthritis and Sacroiliitis: A Post-Hoc Analysis of the Phase 3 DISCOVER-1 and DISCOVER-2 Studies. Lancet Rheumatol. 2021, 3, e715–e723
Mease, P.J.; Smolen, J.S.; Behrens, F.; Nash, P.; Liu Leage, S.; Li, L.; Tahir, H.; Gooderham, M.; Krishnan, E.; Liu-Seifert, H.; et al. A Head-to-Head Comparison of the Efficacy and Safety of Ixekizumab and Adalimumab in Biological-Naïve Patients with Active Psoriatic Arthritis: 24-Week Results of a Randomised, Open-Label, Blinded-Assessor Trial. Ann. Rheum. Dis. 2020, 79, 123–131
Merola, J.F.; Landewé, R.; McInnes, I.B.; Mease, P.J.; Ritchlin, C.T.; Tanaka, Y.; Asahina, A.; Behrens, F.; Gladman, D.D.; Gossec, L.; et al. Bimekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to Tumour Necrosis Factor-α Inhibitors: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial (BE COMPLETE). Lancet 2023, 401, 38–48
Minozzi, S.; Bonovas, S.; Lytras, T.; Pecoraro, V.; González-Lorenzo, M.; Bastiampillai, A.J.; Gabrielli, E.M.; Lonati, A.C.; Moja, L.; Cinquini, M.; et al. Risk of Infections Using Anti-TNF Agents in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis: A Systematic Review and Meta-Analysis. Expert Opin. Drug Saf. 2016, 15, 1243–125
Mishra S., Kancharla H., Dogra S., Sharma A. Comparison of four validated psoriatic arthritis screening tools in diagnosing psoriatic arthritis in patients with psoriasis (COMPAQ Study) Br. J. Dermatol. 2017;176:765–770
Nash, P.; Kirkham, B.; Okada, M.; Rahman, P.; Combe, B.; Burmester, G.R.; Adams, D.H.; Kerr, L.; Lee, C.; Shuler, C.L.; et al. Ixekizumab for the Treatment of Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors: Results from the 24-Week Randomised, Double-Blind, Placebo-Controlled Period of the SPIRIT-P2 Phase 3 Trial. Lancet 2017, 389, 2317–2327.
Ogdie A, Weiss P. The Epidemiology of Psoriatic Arthritis. Rheum Dis Clin North Am. 2015 Nov;41(4):545-68
Östör, A.; van den Bosch, F.; Papp, K.; Asnal, C.; Blanco, R.; Aelion, J.; Alperovich, G.; Lu, W.; Wang, Z.; Soliman, A.M.; et al. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Results from the Randomised, Double-Blind, Phase 3 KEEPsAKE 2 Trial. Ann. Rheum. Dis. 2022, 81, 351–358
Papp, K.; Reich, K.; Leonardi, C.L.; Kircik, L.; Chimenti, S.; Langley, R.G.B.; Hu, C.C.; Stevens, R.M.; Day, R.M.; Gordon, K.B.; et al. Apremilast, an Oral Phosphodiesterase 4 (PDE4) Inhibitor, in Patients with Moderate to Severe Plaque Psoriasis: Results of a Phase III, Randomized, Controlled Trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J. Am. Acad. Dermatol. 2015, 73, 37–49
Paul, C.; Cather, J.; Gooderham, M.; Poulin, Y.; Mrowietz, U.; Ferrandiz, C.; Crowley, J.; Hu, C.; Stevens, R.M.; Shah, K.; et al. Efficacy and Safety of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Moderate-to-severe Plaque Psoriasis over 52 Weeks: A Phase III, Randomized Controlled Trial (ESTEEM 2). Br. J. Dermatol. 2015, 173, 1387–1399
Pollock R.A., Zaman L., Chandran V., Gladman D.D. Epigenome-Wide Analysis of Sperm Cells Identifies IL22 as a Possible Germ Line Risk Locus for Psoriatic Arthritis. PLoS ONE. 2019;14:e0212043
Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, de Vlam K, Fiorentino D, Fitzgerald O, Gottlieb AB, McHugh NJ, Nash P, Qureshi AA, Soriano ER, Taylor WJ., Group for Research and Assessment of
Psoriasis and Psoriatic Arthritis (GRAPPA). Treatment recommendations for
psoriatic arthritis. Ann Rheum Dis. 2009 Sep;68(9):1387-94
Ritchlin, C.; Rahman, P.; Kavanaugh, A.; McInnes, I.B.; Puig, L.; Li, S.; Wang, Y.; Shen, Y.K.; Doyle, M.K.; Mendelsohn, A.M.; et al. Efficacy and Safety of the Anti-IL-12/23 P40 Monoclonal Antibody, Ustekinumab, in Patients with Active Psoriatic Arthritis despite Conventional Non-Biological and Biological Anti-Tumour Necrosis Factor Therapy: 6-Month and 1-Year Results of the Phase 3, Multicentre, Double-Blind, Placebo-Controlled, Randomised PSUMMIT 2 Trial. Ann. Rheum. Dis. 2014, 73, 990–999.
Schinocca, C.; Rizzo, C.; Fasano, S.; Grasso, G.; la Barbera, L.; Ciccia, F.; Guggino, G. Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview. Front. Immunol. 2021, 12, 637829
Seror, R.; Richez, C.; Sordet, C.; Rist, S.; Gossec, L.; Direz, G.; Houvenagel, E.; Berthelot, J.M.; Pagnoux, C.; Dernis, E.; et al. Pattern of Demyelination Occurring during Anti-TNF-α Therapy: A French National Survey. Rheumatology 2013, 52, 868–874
Targan, S.R.; Feagan, B.; Vermeire, S.; Panaccione, R.; Melmed, G.Y.; Landers, C.; Li, D.; Russell, C.; Newmark, R.; Zhang, N.; et al. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients with Moderate-to-Severe Crohn’s Disease. Am. J. Gastroenterol. 2016, 111, 1599–1607
Villani AP, Rouzaud M, Sevrain M, Barnetche T, Paul C, Richard MA, Beylot-Barry M, Misery L, Joly P, Le Maitre M, Aractingi S, Aubin F, Cantagrel A, Ortonne JP, Jullien D. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. J Am Acad Dermatol. 2015 Aug;73(2):242-8
Wells, A.F.; Edwards, C.J.; Kivitz, A.J.; Bird, P.; Nguyen, D.; Paris, M.; Teng, L.; Aelion, J.A. Apremilast Monotherapy in DMARD-Naive Psoriatic Arthritis Patients: Results of the Randomized, Placebo-Controlled PALACE 4 Trial. Rheumatology 2018, 57, 1253
DOI: https://doi.org/10.33024/jmm.v7i3.11813
Refbacks
- There are currently no refbacks.
Copyright (c) 2023 Jurnal Medika Malahayati
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
